

Iris Alroy, Ph.D. has 25 years of experience in drug discovery, preclinical and early clinical development. Dr. Alroy has served as CSO of Anima since 2015, supervising drug discovery and pipeline development in the emerging field of mRNA translation regulation. Prior to Anima, she acted as VP of Discovery at Proteologics and Pharms Corp. and CEO of several startup biotech companies, including Fusimab, Ltd. and ProMining Therapeutics Ltd.

Dr. Alroy earned her doctorate in Cell Biology from Cornell University and completed a post-doctoral fellowship at the Weizmann Institute. She has authored more than 20 scientific articles in peer-reviewed journals.